Top Markets
#1 Akedo Akedo +179.90%
#2 TENDIES TENDIES +90.81%
#3 Threshold Network Threshold Network +48.52%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.98%
#6 Bitway Bitway +28.51%
#7 MultiversX MultiversX +25.94%
#8 Cash Cat Cash Cat +23.23%
#9 Palladium Network Palladium Network +22.70%
#10 aelf aelf +19.29%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Healthcare
P/E ratio for Regulus Therapeutics Inc. (RGLS)
P/E ratio as of September 2026 TTM: -9.95
According to Regulus Therapeutics Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.95. At the end of 2023 the company had a P/E ratio of -0.81.
P/E ratio history for Regulus Therapeutics Inc. from 2010 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -9.95 418.29%
2024 -1.92 137.67%
2023 -0.81 9.47%
2022 -0.74 -25.16%
2021 -0.99 -67.15%
2020 -3.00 263.34%
2019 -0.83 396.22%
2018 -0.17 -88.93%
2017 -1.50 3.59%
2016 -1.45 -81.94%
2015 -8.04 -35.55%
2014 -12.48 -18.09%
2013 -15.23 412.52%
2012 -2.97 1,995.98%
2011 -0.14 104.62%
2010 -0.07 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -415.93%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -470.32%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 76.73%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 134.33%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.